Dunno mate, anything would be great.
Perhaps screening of patients in US has commenced.
Patient 1 in Australia has been injected.
New CEO? This is surely due this quarter
Left field would be repurposing of another molecule they have come across for another condition. This was something they are "planned to do" in an announcement in Q4 2020.....this is the mantra of PAR apparently, a company that will repurpose existing molecules.....They have 1 molecule so far in their portfolio
Chart, page-2626
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.010(5.00%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.5¢ | 21.0¢ | $27.99K | 131.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20896 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 22924 | 4 |
View Market Depth
| Last trade - 10.32am 03/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |